254 related articles for article (PubMed ID: 25557559)
1. Emerging drugs for squamous cell lung cancer.
Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
[TBL] [Abstract][Full Text] [Related]
2. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
3. Mouse models in squamous cell lung cancer: impact for drug discovery.
Singh AP; Adrianzen Herrera D; Zhang Y; Perez-Soler R; Cheng H
Expert Opin Drug Discov; 2018 Apr; 13(4):347-358. PubMed ID: 29394493
[TBL] [Abstract][Full Text] [Related]
4. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
[TBL] [Abstract][Full Text] [Related]
5. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
Genova C; Rijavec E; Grossi F
Expert Rev Anticancer Ther; 2016; 16(1):1-4. PubMed ID: 26567561
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
9. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
10. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Vanni I; Boccardo S; Alama A; Grossi F
Expert Opin Investig Drugs; 2017 May; 26(5):551-561. PubMed ID: 28388262
[TBL] [Abstract][Full Text] [Related]
11. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn PA; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Wakelee H; Thatcher N
J Thorac Oncol; 2018 Feb; 13(2):165-183. PubMed ID: 29175116
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
13. [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].
Dong M; Li T; Chen J
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):116-120. PubMed ID: 29526179
[TBL] [Abstract][Full Text] [Related]
14. Squamous non-small cell lung cancer as a distinct clinical entity.
Oliver TG; Patel J; Akerley W
Am J Clin Oncol; 2015 Apr; 38(2):220-6. PubMed ID: 25806712
[TBL] [Abstract][Full Text] [Related]
15. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
16. Refining the treatment of NSCLC according to histological and molecular subtypes.
Thomas A; Liu SV; Subramaniam DS; Giaccone G
Nat Rev Clin Oncol; 2015 Sep; 12(9):511-26. PubMed ID: 25963091
[TBL] [Abstract][Full Text] [Related]
17. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Jeong EH; Lee TG; Ko YJ; Kim SY; Kim HR; Kim H; Kim CH
Cell Oncol (Dordr); 2018 Dec; 41(6):663-675. PubMed ID: 30178167
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
Devarakonda S; Morgensztern D; Govindan R
Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]